Identification of a variable number of tandem repeats polymorphism and characterization of LEF-1 response elements in the promoter of the IDO1 gene

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Soichot, Marion ^a   Hennart, Benjamin ^a   Al Saabi, Alaa ^a   Leloire, Audrey ^b   Froguel, Philippe ^b,c   Levy Marchal, Claire ^d   Poulain Godefroy, Odile ^b   Allorge, Delphine ^a  

^a France Institut Pasteur de Lille   (France)

^b Institut Pasteur de Lille   (France)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; DNA; INDOLEAMINE 2,3 DIOXYGENASE; LEF1 PROTEIN, HUMAN; LYMPHOID ENHANCER FACTOR 1; TRYPTOPHAN;

ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE; GENE FREQUENCY; GENE INTERACTION; GENE OVEREXPRESSION; GENOTYPE; HUMAN; IDO1 GENE; LEF 1 GENE; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN DNA INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; VARIABLE NUMBER OF TANDEM REPEAT; ADULT; BLOOD; DNA RESPONSIVE ELEMENT; EXON; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETICS; INTRON; METABOLISM; MOLECULAR GENETICS;

BASE SEQUENCE; DNA; EXONS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTRONS; LYMPHOID ENHANCER-BINDING FACTOR 1; MALE; MINISATELLITE REPEATS; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC; TRYPTOPHAN; YOUNG ADULT;

EID: 80053193640     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025470     Document Type: Article

References (55)

1. Takikawa O, (2005) Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. Biochem Biophys Res Commun 338: 12-19.
2. Mellor AL, Munn DH, (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4: 762-774.
3. Mellor A, (2005) Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem Biophys Res Commun 338: 20-24.
4. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, et al. (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1191-1193.
5. Zhu BT, (2010) Development of selective immune tolerance towards the allogeneic fetus during pregnancy: Role of tryptophan catabolites (Review). Int J Mol Med 25: 831-835.
6. Prendergast GC, (2008) Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27: 3889-3900.
7. Macchiarulo A, Camaioni E, Nuti R, Pellicciari R, (2009) Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease. Amino Acids 37: 219-229.
8. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC, (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11: 312-319.
9. Muller AJ, Malachowski WP, Prendergast GC, (2005) Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets 9: 831-849.
10. Lesch KP, Gutknecht L, (2005) Pharmacogenetics of the serotonin transporter. Prog. Neuropsychopharmacol. Biol Psychiatry 29: 1062-1073.
11. Nemeth H, Robotka H, Toldi J, Vecsei L, (2007) Kynurenines in the central nervous system: recent developments. Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal 7: 45-56.
12. Németh H, Toldi J, Vécsei L, (2006) Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J Neural Transm 70 (Suppl): 285-304.
13. Oxenkrug GF, (2011) Interferon-gamma-inducible kynurenines/pteridines inflammation cascade: implications for aging and aging-associated psychiatric and medical disorders. J Neural Transm 118: 75-85.
14. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, et al. (2002) Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 22: 86-90.
15. Myint AM, Schwarz MJ, Steinbusch HWM, Leonard BE, (2009) Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis 24: 55-68.
16. Takikawa O, Kuroiwa T, Yamazaki F, Kido R, (1988) Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem 263: 2041-2048.
17. Konan KV, Taylor MW, (1996) Importance of the two interferon-stimulated response element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase gene. J Biol Chem 271: 19140-19145.
18. Schröcksnadel K, Wirleitner B, Winkler C, Fuchs D, (2006) Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 364: 82-90.
19. Lögters TT, Laryea MD, Altrichter J, Sokolowski J, Cinatl J, et al. (2009) Increased plasma kynurenine values and kynurenine-tryptophan ratios after major trauma are early indicators for the development of sepsis. Shock 32: 29-34.
20. Nishizawa H, Hasegawa K, Suzuki M, Kamoshida S, Kato T, et al. (2007) The etiological role of allogeneic fetal rejection in pre-eclampsia. Am J Reprod Immunol 58: 11-20.
21. Corm S, Berthon C, Imbenotte M, Biggio V, Lhermitte M, et al. (2009) Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma. Leuk Res 33: 490-494.
22. Huttunen R, Syrjänen J, Aittoniemi J, Oja SS, Raitala A, et al. (2010) High activity of indoleamine 2,3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients. Shock 33: 149-154.
23. Kato A, Suzuki Y, Suda T, Suzuki M, Fujie M, et al. (2010) Relationship between an increased serum kynurenine/tryptophan ratio and atherosclerotic parameters in hemodialysis patients. Hemodial Int 14: 418-424.
24. Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, et al. (2010) Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 67: 361-365.
25. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, et al. (2005) IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 10: 538-544.
26. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, et al. (2010) CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 15: 393-403.
27. Oxenkrug GF, (2007) Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging. Ann N Y Acad Sci 1122: 35-49.
28. Raitala A, Pertovaara M, Karjalainen J, Oja SS, Hurme M, (2005) Association of interferon-gamma +874(T/A) single nucleotide polymorphism with the rate of tryptophan catabolism in healthy individuals. Scand J Immunol 61: 387-390.
29. Oxenkrug G, Perianayagam M, Mikolich D, Requintina P, Shick L, et al. (2011) Interferon-gamma (+874) T/A genotypes and risk of IFN-alpha-induced depression. J Neural Transm 118: 271-274.
30. Arefayene M, Philips S, Cao D, Mamidipalli S, Desta Z, et al. (2009) Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity. Pharmacogenet Genomics 19: 464-476.
31. Chon SY, Hassanain HH, Gupta SL, (1996) Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem 271: 17247-17252.
32. Robinson CM, Shirey KA, Carlin JM, (2003) Synergistic transcriptional activation of indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha. J Interferon Cytokine Res 23: 413-421.
33. Robinson CM, Hale PT, Carlin JM, (2005) The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 25: 20-30.
34. Robinson CM, Hale PT, Carlin JM, (2006) NF-kappa B activation contributes to indoleamine dioxygenase transcriptional synergy induced by IFN-gamma and tumor necrosis factor-alpha. Cytokine 35: 53-61.
35. Vonica A, Weng W, Gumbiner BM, Venuti JM, (2000) TCF is the nuclear effector of the beta-catenin signal that patterns the sea urchin animal-vegetal axis. Dev Biol 217: 230-243.
36. Murray MF, (2007) The human indoleamine 2,3-dioxygenase gene and related human genes. Curr Drug Metab 8: 197-200.
37. Nishizawa H, Kato T, Ota S, Nishiyama S, Pryor-Koishi K, et al. (2010) Genetic variation in the indoleamine 2,3-dioxygenase gene in pre-eclampsia. Am J Reprod Immunol 64: 68-76.
38. Pastinen T, Hudson TJ, (2004) Cis-acting regulatory variation in the human genome. Science 306: 647-650.
39. Pertovaara M, Raitala A, Juonala M, Lehtimäki T, Huhtala H, et al. (2007) Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol 148: 106-111.
40. Nishizawa S, Benkelfat C, Young SN, Leyton M, Mzengeza S, et al. (1997) Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci U S A 94: 5308-5313.
41. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R, (2010) The new « 5-HT » hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 35: 702-721.
42. Ueno A, Cho S, Cheng L, Wang J, Hou S, et al. (2007) Transient upregulation of indoleamine 2,3-dioxygenase in dendritic cells by human chorionic gonadotropin downregulates autoimmune diabetes. Diabetes 56: 1686-1693.
43. Kawaguchi R, Shimokawa T, Umehara N, Nunomura S, Tanaka T, et al. (2008) Priming of peripheral monocytes with prolactin (PRL) sensitizes IFN-[gamma]-mediated indoleamine 2,3-dioxygenase (IDO) expression without affecting IFN-[gamma] signaling. J Reprod Immunol 77: 117-125.
44. Zhu WH, Lu CZ, Huang YM, Link H, Xiao BG, (2007) A putative mechanism on remission of multiple sclerosis during pregnancy: estrogen-induced indoleamine 2,3-dioxygenase by dendritic cells. Mult Scler 13: 33-40.
45. Orabona C, Grohmann U, (2011) Indoleamine 2,3-dioxygenase and regulatory function: tryptophan starvation and beyond. Methods Mol Biol 677: 269-280.
46. Carretti N, Florio P, Bertolin A, Costa CVL, Allegri G, et al. (2005) Serum fluctuations of total and free tryptophan levels during the menstrual cycle are related to gonadotrophins and reflect brain serotonin utilization. Hum Reprod 20: 1548-1553.
47. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, et al. (2005) MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21: 2933-2942.
48. Merrill BJ, Gat U, DasGupta R, Fuchs E, (2001) Tcf3 and Lef1 regulate lineage differentiation of multipotent stem cells in skin. Genes Dev 15: 1688-1705.
49. Perrais M, Chen X, Perez-Moreno M, Gumbiner BM, (2007) E-cadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling independently of other cell interactions. Mol Biol Cell 18: 2013-2025.
50. Hurlstone A, Clevers H, (2002) T-cell factors: turn-ons and turn-offs. EMBO J 21: 2303-2311.
51. Hebenstreit D, Giaisi M, Treiber MK, Zhang X-B, Mi H-F, et al. (2008) LEF-1 negatively controls interleukin-4 expression through a proximal promoter regulatory element. J Biol Chem 283: 22490-22497.
52. Arce L, Pate KT, Waterman ML, (2009) Groucho binds two conserved regions of LEF-1 for HDAC-dependent repression. BMC Cancer 9: 159.
53. Bouatia-Naji N, Marchand M, Cavalcanti-Proença C, Daghmoun S, Durand E, et al. (2009) Smallness for gestational age interacts with high mobility group A2 gene genetic variation to modulate height. Eur J Endocrinol 160: 557-560.
54. Jaquet D, Collin D, Lévy-Marchal C, Czernichow P, (2004) Adult height distribution in subjects born small for gestational age. Horm Res 62: 92-96.
55. Schefold JC, Zeden J-P, Fotopoulou C, von Haehling S, Pschowski R, et al. (2009) Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant 24: 1901-1908.